Is Trident Lifeline overvalued or undervalued?

As of 29 September 2025, the valuation grade for Trident Lifeline has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 20.27, while the EV to EBITDA ratio is 17.23, and the PEG ratio is notably low at 0.24, indicating potential concerns about growth relative to its price.
In comparison to its peers, Trident Lifeline's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 33.27, but higher than Dr. Reddy's Labs at 18.15, which is classified as attractive. Additionally, the company's ROE of 9.87% and ROCE of 5.36% suggest that it is not generating returns as effectively as some of its peers in the pharmaceuticals sector. The stock has underperformed against the Sensex over the past year, with a return of -12.16% compared to the Sensex's -6.08%, further supporting the view that Trident Lifeline is currently overvalued.